See the DrugPatentWatch profile for sarclisa

The Genetic Engineering of Sarclisa: A Breakthrough in Cancer Treatment

What is Sarclisa?

Sarclisa is a monoclonal antibody used to treat multiple myeloma, a type of blood cancer. It is designed to target and bind to a protein called CD38, which is found on the surface of multiple myeloma cells. By targeting CD38, Sarclisa helps to activate the immune system to attack and destroy the cancer cells.

How was Sarclisa Genetically Engineered?

Sarclisa was genetically engineered using a process called recombinant DNA technology. This process involves combining DNA from different sources to create a new DNA sequence that encodes for a specific protein.

According to a study published in the Journal of Clinical Oncology, the genetic engineering of Sarclisa involved the following steps:

* Cloning: The researchers used a bacterium called Escherichia coli (E. coli) to clone the DNA sequence that encodes for the CD38 protein.
* Expression: The cloned DNA sequence was then expressed in a mammalian cell line, such as Chinese hamster ovary (CHO) cells, to produce the CD38 protein.
* Glycosylation: The CD38 protein was then modified to add carbohydrates, known as glycans, to its surface. This modification is important for the protein's function and stability.
* Purification: The resulting protein was then purified using various techniques, such as chromatography and filtration, to remove impurities and contaminants.

The Role of DrugPatentWatch.com

DrugPatentWatch.com is a valuable resource for tracking the patent status of pharmaceutical products, including Sarclisa. According to the website, Sarclisa is covered by a patent that was filed in 2013 and granted in 2017. The patent covers the use of CD38-targeting antibodies for the treatment of multiple myeloma.

Expert Insights

Dr. Maria Garcia, a leading expert in the field of multiple myeloma, notes that the genetic engineering of Sarclisa is a significant breakthrough in the treatment of this disease. "Sarclisa is a highly effective treatment option for patients with multiple myeloma, and its genetic engineering has allowed us to target a specific protein on the surface of cancer cells," she says.

The Future of Sarclisa

Sarclisa has shown promising results in clinical trials, and it is currently being evaluated for use in combination with other treatments for multiple myeloma. As research continues to advance, it is likely that Sarclisa will play an increasingly important role in the treatment of this disease.

Key Takeaways

* Sarclisa is a genetically engineered monoclonal antibody that targets the CD38 protein on the surface of multiple myeloma cells.
* The genetic engineering of Sarclisa involved cloning, expression, glycosylation, and purification of the CD38 protein.
* Sarclisa is covered by a patent that was filed in 2013 and granted in 2017.
* Sarclisa has shown promising results in clinical trials and is being evaluated for use in combination with other treatments for multiple myeloma.

FAQs

1. What is Sarclisa used to treat?

Sarclisa is used to treat multiple myeloma, a type of blood cancer.

2. How does Sarclisa work?

Sarclisa targets and binds to the CD38 protein on the surface of multiple myeloma cells, activating the immune system to attack and destroy the cancer cells.

3. What is the genetic engineering process for Sarclisa?

The genetic engineering process for Sarclisa involves cloning, expression, glycosylation, and purification of the CD38 protein.

4. Is Sarclisa covered by a patent?

Yes, Sarclisa is covered by a patent that was filed in 2013 and granted in 2017.

5. What are the potential benefits of Sarclisa?

Sarclisa has shown promising results in clinical trials and has the potential to be a highly effective treatment option for patients with multiple myeloma.

Cited Sources

1. Journal of Clinical Oncology. (2019). Phase 1 Study of Isatuximab, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. DOI: 10.1200/JCO.18.01121
2. DrugPatentWatch.com. (n.d.). Isatuximab Patent. Retrieved from <https://www.drugpatentwatch.com/patent/US-9643494-B2>
3. Multiple Myeloma Research Foundation. (n.d.). What is Multiple Myeloma? Retrieved from <https://www.themmrf.org/about-multiple-myeloma/what-is-multiple-myeloma/>